Optimizing development of anti-TNFα biosimilars based on 10 years’ experience

Abstract

Routine regulatory requirements for large comparative efficacy trials (CETs) to support marketing approval of monoclonal antibody (mAb) biosimilars have been the focus of extensive debate in the last few years. This review examines the mounting evidence, accumulated over the past decade, focusing on relevant literature and data published in the European Product Assessment Reports (EPARs) for the fifteen anti-TNFα biosimilars approved to date. The potential for residual uncertainties that may require resolution through CETs following comparative physico-chemical, in-vitro potency, and single dose studies in healthy subjects is examined. It is noted that structural and physicochemical differences between biosimilars and reference products are detectable using modern analytical methods at levels well below those that could impact clinical outcomes, and that in vitro potency testing is fully capable of revealing clinically relevant differences. Additionally, comparative pharmacokinetic studies in healthy participants provide a sensitive assessment of potential differences in drug exposure and immunogenicity. The added value of CETs is further questioned in the light of the fact that anti-TNFα’s display a flat dose-response relationship, meaning that unlike cell-based assays, CETs have limited sensitivity to detect potency differences. Initial concerns about extrapolating data from rheumatoid arthritis studies to support marketing approval of other indications such as inflammatory bowel disease for which not all anti-TNFα’s are effective have been alleviated by post-approval studies. Additionally, as of the end of 2024, no cases where clinical efficacy data were necessary to resolve residual quality concerns have arisen following regulatory assessment of 56 mAb biosimilars and fusion proteins. CETs add significant cost and delay to the development of biosimilars and the time is now ripe to re-examine the need for these CET’s and for further evolution in regulatory thinking.

Keywords

Adalimumab / anti-TNFα / biosimilar / etanercept / infliximab / clinical development / regulatory

References

[1] Nick C. Streamlining biosimilar development based on 20 years’ experience. Expert Opin Biol Ther. 2024; 24: 571-81.

[2] Assessment report - Inflectra - International non-proprietary name: Infliximab - Procedure No. EMEA/H/C/002778/000 [Internet]. European Medicines Agency; c2016 [cited 2016 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/inflectra-epar-public-assessment-report_en.pdf

[3] Assessment report - Flixabi International non-proprietary name: infliximab - Procedure No. EMEA/H/C/004020/000 [Internet]. European Medicines Agency; c2016 [cited 2024 November 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/flixabi-epar-public-assessment-report_en.pdf

[4] Assessment report - Zessly - International non-proprietary name: infliximab - Procedure No. EMEA/H/C/004647/0000 [Internet]. European Medicines Agency; c2018 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/zessly-epar-public-assessment-report_en.pdf

[5] Assessment report - Benepali - International non-proprietary name: etanercept - Procedure No. EMEA/H/C/004007/0000 [Internet]. European Medicines Agency; c2016 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/benepali-epar-public-assessment-report_en.pdf

[6] Assessment report - Erelzi - International non-proprietary name: etanercept - Procedure No. EMEA/H/C/004192/0000 [Internet]. European Medicines Agency; c2017 [cited 2024 November 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/erelzi-epar-public-assessment-report_en.pdf

[7] Assessment report - Nepexto - International non-proprietary name: etanercept - Procedure No. EMEA/H/C/004711/0000 [Internet]. European Medicines Agency; c2020 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/nepexto-epar-public-assessment-report_en.pdf

[8] Assessment report - Amgevita - International non-proprietary name: adalimumab - Procedure No. EMEA/H/C/004212/0000 [Internet]. European Medicines Agency; c2017 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/amgevita-epar-public-assessment-report_en.pdf

[9] Assessment report - Imraldi - International non-proprietary name: adalimumab - Procedure No. EMEA/H/C/004279/0000 [Internet]. European Medicines Agency; c2017 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/imraldi-epar-public-assessment-report_en.pdf

[10] Assessment report - Hulio - International non-proprietary name: adalimumab - Procedure No. EMEA/H/C/004429/000 [Internet]. European Medicines Agency; c2018 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/hulio-epar-public-assessment-report_en.pdf

[11] Assessment report - Hyrimoz - International non-proprietary name: adalimumab - Procedure No. EMEA/H/C/004320/0000 [Internet]. European Medicines Agency; c2018 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/hyrimoz-epar-public-assessment-report_en.pdf

[12] Assessment report - Idacio - International non-proprietary name: adalimumab - Procedure No. EMEA/H/C/004475/000 [Internet]. European Medicines Agency; c2019 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/idacio-epar-public-assessment-report_en.pdf

[13] Assessment report - Amsparity - International non-proprietary name: adalimumab - Procedure No. EMEA/H/C/004879/0000 [Internet]. European Medicines Agency; c2019 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/amsparity-epar-public-assessment-report_en.pdf

[14] Assessment report - Yuflyma - International non-proprietary name: adalimumab - Procedure No. EMEA/H/C/005188/0000 [Internet]. European Medicines Agency; c2021 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/yuflyma-epar-public-assessment-report_en.pdf

[15] Assessment report - Idacio - International non-proprietary name: adalimumab - Procedure No. EMA/124342/2019 [Internet]. European Medicine Agency; c2019 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/idacio-epar-public-assessment-report_en.pdf

[16] Assessment report - Libmyris - International non-proprietary name: adalimumab - Procedure No. EMEA/H/C/005947/0000 [Internet]. European Medicines Agency; c2022 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/libmyris-epar-public-assessment-report_en.pdf

[17] Assessment report - Cyltezo - International non-proprietary name: adalimumab - Procedure No. EMEA/H/C/004319/0000 [Internet]. European Medicines Agency; c2017 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/cyltezo-epar-public-assessment-report_en.pdf

[18] Sheridan C. First generic biologics finally approved. Nat Rev Drug Discov. 2006; 5: 445.

[19] Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol. 2008; 26: 985-90.

[20] Schneider CK, Vleminckx C, Gravanis I, Ehmann F, Trouvin JH, Weise M, et al. Setting the stage for biosimilar monoclonal antibodies. Nat Biotechnol. 2012; 30: 1179-85.

[21] Kim S, Song J, Park S, Ham S, Paek K, Kang M, et al. Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar. MAbs. 2017; 9: 704-14.

[22] Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011; 29: 310-2.

[23] Kozlowski S, Swann P. Current and future issues in the manufacturing and development of monoclonal antibodies. Adv Drug Deliv Rev. 2006; 58: 707-22.

[24] Liu H, Ponniah G, Zhang HM, Nowak C, Neill A, Gonzalez-Lopez N, et al. In vitro and in vivo modifications of recombinant and human IgG antibodies. MAbs. 2014; 6: 1145-54.

[25] Edwards E, Livanos M, Krueger A, Dell A, Haslam SM, Mark Smales C, et al. Strategies to control therapeutic antibody glycosylation during bioprocessing: Synthesis and separation. Biotechnol Bioeng. 2022; 119: 1343-58.

[26] Schuster J, Koulov A, Mahler HC, Detampel P, Huwyler J, Singh S, et al. In Vivo Stability of Therapeutic Proteins. Pharm Res. 2020; 37: 23.

[27] Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res. 2004; 21: 897-903.

[28] Rosenberg A, Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products, part 2: Considering host-specific and product-specific factors impacting immunogenicity. Biopharm Int. 2004; 17: 34-42.

[29] Rosenberg AS, Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products, part 3: effects of manufacturing changes in immunogenicity and the utility of animal immunogenicity studies. Biopharm Int. 2005; 18: 22-6.

[30] Eon-Duval A, Broly H, Gleixner R. Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach. Biotechnol Prog. 2012; 28: 608-22.

[31] Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol. 2016; 22: 9300-13.

[32] Assessment report - Enbrel - International non-proprietary name: etanercept - Procedure No. EMEA/H/C/000262 [Internet]. European Medicines Agency; c2009 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/scientific-discussion/enbrel-epar-scientific-discussion_en.pdf

[33] Assessment report - Cimzia - International non-proprietary name: certolizumab pegol - Procedure No. EMEA/H/C/001037 [Internet]. European Medicines Agency; c2009 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/cimzia-epar-public-assessment-report_en.pdf

[34] Koelink PJ, Bloemendaal FM, Li B, Westera L, Vogels EWM, van Roest M, et al. Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling. Gut. 2020; 69: 1053-63.

[35] Sipos O, Török A, Kalic T, Duda E, Filkor K. Reverse Signaling Contributes to Control of Chronic Inflammation by anti-TNFα Therapeutics. Antibodies. 2015; 4: 123-40.

[36] Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues [Internet]. European Medicines Agency; c2015 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-revision-1_en.pdf

[37] Immunogenicity Testing of Therapeutic Protein Products - Developing and Validating Assays for Anti-Drug Antibody Detection Guidance for Industry [Internet]. U.S. Food and Drug Administration; c2019 [cited 2024 Nov 15]. Available from: https://www.fda.gov/media/119788/download

[38] Song S, Yang L, Trepicchio WL, Wyant T. Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance. J Immunol Res. 2016; 2016: 3072586.

[39] Assessment report - Humira - International non-proprietary name: adalimumab - Procedure No. EMEA/H/C/000481 [Internet]. European Medicines Agency; c2004 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/scientific-discussion/humira-epar-scientific-discussion_en.pdf

[40] Assessment report - Remicade - International non-proprietary name: infliximab - EMEA/H/C/000240 [Internet]. European Medicines Agency; c1999 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/scientific-discussion/remicade-epar-scientific-discussion_en.pdf

[41] Doshi S, Wang H, Chow V. Establishing PK Equivalence Between Adalimumab and ABP 501 in the Presence of Antidrug Antibodies Using Population PK Modeling. Clin Ther. 2022; 44: 111-22.

[42] Guidelines on evaluation of biosimilars Replacement of Annex 2 of WHO Technical Report Series, No. 977 [Internet]. World Health Organizations (WHO); c2022 [cited 2024 Nov 15]. Available from: https://cdn.who.int/media/docs/default-source/biologicals/bs-documents-(ecbs)/annex-3---who-guidelines-on-evaluation-of-biosimilars_22-apr-2022.pdf

[43] Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry [Internet]. U.S. Food and Drug Administration; c2015 [cited 2024 Nov 15]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-product

[44] Almoallim H, Al Saleh J, Badsha H, Ahmed HM, Habjoka S, Menassa JA, et al. A Review of the Prevalence and Unmet Needs in the Management of Rheumatoid Arthritis in Africa and the Middle East. Rheumatol Ther. 2021; 8: 1-16.

[45] Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM; Global Psoriasis Atlas. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020; 369: m1590.

[46] EMEA/446762/2009 Assessment report for Simponi - International Nonproprietary Name: golimumab - Procedure No. EMEA/H/C/000992 [Internet]. European Medicines Agency; c2009 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/simponi-epar-public-assessment-report_en.pdf

[47] Kirsch-Stefan N, Guillen E, Ekman N, Barry S, Knippel V, Killalea S, et al. Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars? BioDrugs. 2023; 37: 855-71.

[48] Bielsky MC, Cook A, Wallington A, Exley A, Kauser S, Hay JL, et al. Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial. Drug Discov Today. 2020;[Epub ahead of print].

[49] Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al.; NOR-SWITCH study group. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017; 389: 2304-16.

[50] Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019; 393: 1699-707.

[51] Zymfentra Full Prescribing Information [Internet]. U.S. Food and Drug Administration; [cited 2024 Nov 15]. Available from: https://www.zymfentra.com/wp-content/uploads/2023/10/zemfentra_fda_approved_highlights_pi_pi_contents_fpi.pdf

[52] The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions E1 [Internet]. ICH; c1994 [cited 2024 Nov 15]. Available from: https://database.ich.org/sites/default/files/E1_Guideline.pdf

[53] Implementation of the Biologics Price Competition and Innovation Act of 2009 [Internet]. U.S Food and Drug Administration; [cited 2024 Nov 15]. Available from: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/implementation-biologics-price-competition-and-innovation-act-2009

[54] Herndon TM, Ausin C, Brahme NN, Schrieber SJ, Luo M, Andrada FC, et al. Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis. PLoS One. 2023; 18: e0292231.

[55] Patients switching back and forth from CYLTEZO to Humira multiple times saw no difference in safety, efficacy, immunogenicity, or pharmacokinetics [Internet]. Boehringer Ingelheim; c2024 [cited 2024 Nov 15]. Available from: https://pro.boehringer-ingelheim.com/us/products/cyltezo/evidence/switching-study

[56] Hyrimoz prescribing information [Internet]. Sandoz Group AG; [cited 2024 Nov 15]. Available from: https://www.hyrimoz.com/pro/totality-of-evidence/adaccess.html

[57] Biosimilar Multidisciplinary Evaluation and Review (BMER) BLA 761285 and BLA 761331 ABP 654, a proposed interchangeable biosimilar to US-licensed Stelara (ustekinumab) [Internet]. U.S. Food and Drug Administration; c2024 [cited 2024 Nov 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761285Orig1s000,761331Orig1s000MultidisciplineR.pdf

[58] What biosimilars have been approved in the United States? Medically reviewed by Judith Stewart [Internet]. Drugs.com; [cited 2024 Dec 24]. Available from: https://www.drugs.com/medical-answers/many-biosimilars-approved-united-states-3463281/

[59] IPRP Biosimilars Working Group Workshop: “Increasing the Efficiency of Biosimilar Development Programs-Re-evaluating the Need for Comparative Clinical Efficacy Studies (CES)” [Internet]. U.S. Food and Drug Administration; [cited 2024 Nov 15]. Available from: https://www.fda.gov/media/172197/download

[60] Concept paper for the development of a Reflection Paper on a tailored clinical approach in Biosimilar development [Internet]. European Medicines Agency; c2024 [cited 2024 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/other/concept-paper-development-reflection-paper-tailored-clinical-approach-biosimilar-development_en.pdf

[61] Guidance on the licensing of biosimilar products [Internet]. GOV.UK; [cited 2024 Nov 15]. Available from: https://www.gov.uk/government/publications/guidance-on-the-licensing-of-biosimilar-products/guidance-on-the-licensing-of-biosimilar-products

[62] Guidelines on evaluation of biosimilars. Replacement of Annex 2 of WHO Technical Report Series, No. 977 [Internet]. WHO; c2024 [cited 2024 Dec 04]. Available from: https://www.who.int/publications/m/item/guidelines-on-evaluation-of-biosimilars